In the event of a Change in Control of Array in which the Acquirer is developing or commercializing [ * ] in the Field, any Development and Commercialization of a [ * ] , Binimetinib and/or Encorafenib combination by the Parties shall be conducted subject to appropriate firewall procedures to segregate such activities (and the personnel conducting such activities) from the activities performed by or on behalf of Acquirer with respect to [ * ] it is developing or commercializing, to ensure that [ * ] is disclosed to employees of the Acquirer who are developing or commercializing the Acquirer’s [ * ] .